Skip to content

Abstract TH184: Demographic Variation in Cardiorenal Complications Among Patients With Resistant Hypertension and Heart Failure With Preserved Ejection Fraction

Oct 2026 · HYPERTENSION · 0 citations

Abstract

Background: Resistant hypertension and heart failure with preserved ejection fraction (HFpEF) frequently coexist, yet the long-term burden of downstream cardiorenal complications, and whether that burden is equally distributed across demographic groups, remains poorly characterized. Decade-long real-world data are needed to define the natural history of this phenotype and identify populations warranting closer surveillance. Hypothesis: Among adults with resistant hypertension and HFpEF, incidence of progression to systolic heart failure, end-stage renal disease, atrial fibrillation, cardiogenic shock, and defibrillator implantation varies substantially by race, sex, and age. Methods: Using the TriNetX Global Collaborative Network (176 healthcare organizations, approximately 120 million patients), we identified 12,401 adults aged 18 years or older with resistant hypertension (ICD-10 I1A.0) and HFpEF, free of prior systolic heart failure (I50.20-I50.23) at baseline. Five events of interest were assessed over an 11-year window from January 2015 to January 2026: progression to systolic heart failure, defibrillator implantation, cardiogenic shock, end-stage renal disease, and incident atrial fibrillation. Incidence proportion and prevalence were calculated overall and stratified by age, sex, race, and ethnicity. Results: Progression to systolic heart failure occurred in 26.4% of patients, atrial fibrillation in 29.0%, end-stage renal disease in 20.7%, defibrillator implantation in 2.7%, and cardiogenic shock in 2.7%. Substantial racial disparities emerged for end-stage renal disease, ranging from 15.4% in White patients to 25.2% in Black patients, 33.2% in Asian patients, and 36.9% in Native Hawaiian or Pacific Islander patients. A similar gradient was observed for systolic heart failure progression, ranging from 24.5% in White to 32.0% in Other Race patients[RT1] . Male sex was associated with higher incidence across all outcomes, most notably defibrillator implantation, roughly 54% more frequent in men (3.3% versus 2.1%). Atrial fibrillation incidence more than doubled with age, from 21.5% at 45-49 years to 47.3% at 75-79 years, while end-stage renal disease incidence paradoxically declined with advancing age. Conclusions: In a large real-world cohort with resistant hypertension and HFpEF, nearly one in three patients progressed to systolic heart failure or developed atrial fibrillation over a decade, with end-stage renal disease disproportionately affecting Black, Asian, Native Hawaiian, and Pacific Islander patients. These findings identify resistant hypertension with HFpEF as a high-burden phenotype with pronounced racial disparities in renal outcomes, supporting targeted surveillance and earlier nephroprotective intervention in disproportionately affected populations.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.